Medivation, Inc. (NASDAQ:MDVN)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.

Recs

0
Player Avatar pchop123 (76.57) Submitted: 6/21/2012 4:24:02 PM : Outperform Start Price: $43.58 MDVN Score: +5.56

The Promise od the new prostrate drug !!!!

Report this Post Reply

Featured Broker Partners


Advertisement